Barclays (LON:BARC) analyst Peter Lawson maintained a Buy rating on Epizyme (NASDAQ:EPZM) on Tuesday, setting a price target of $17, which is approximately 63.30% above the present share price of $10.41.
Lawson expects Epizyme to post earnings per share (EPS) of -$0.55 for the first quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Epizyme, with an average price target of $23.5.
The analysts price targets range from a high of $36 to a low of $14.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $3.57 million and a net profit of -$54.36 million. The company's market cap is $1.06 billion.
According to TipRanks.com, Barclays analyst Peter Lawson is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 13.9% and a 50.20% success rate.
Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.